Acute exacerbations in patients with progressive pulmonary fibrosis.

ABSTRACT:

Background

Acute exacerbations of fibrosing interstitial lung diseases (ILDs) are associated with high mortality. We used prospective data from the INBUILD trial to investigate risk factors for acute exacerbations and the impact of these events in patients with progressive pulmonary fibrosis.

Methods

Patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF) were randomised to receive nintedanib or placebo. Associations between baseline characteristics and time to first acute exacerbation were assessed using pooled data from both treatment groups using Cox proportional hazard models, firstly univariable models and then a multivariable model using forward stepwise selection. The risk of death was estimated based on the Kaplan-Meier method.

Resu

SUBMITTER: Kreuter M 

PROVIDER: S-EPMC11610068 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature